Search Results
Your search for ,had matches 18492 pages
Showing 16001 - 16050American College of Physicians Releases Best Practice Advice for Cervical Cancer Screening in Average-Risk Women
In April 2015, the American College of Physicians (ACP) released its clinical advice guideline, Cervical Cancer Screening in Average-Risk Women: Best Practice Advice From the Clinical Guidelines Committee of the American College of Physicians.1 The guideline aims to reduce the overuse of cervical...
PARP Inhibitors Have ‘Clear Benefit’ for Patients With Ovarian Cancer and BRCA Mutations, but When and at What Cost?
PARP inhibitors offer a promising alternative for targeted therapy in ovarian cancer” and have “clear benefit in BRCA-mutation carriers,” but questions remain about when is the best time to use them and the cost-effectiveness of maintenance therapy, Elizabeth M. Swisher, MD, of the University of...
Moffitt Cancer Center Hosts First HPV Summit
In February 2015, the President’s Cancer Panel reported that human papillomavirus (HPV) vaccination uptake among boys and girls was falling drastically short of target rates, posing “a serious but correctable threat to progress against cancer.” In response, the National Cancer Institute (NCI)...
HPV-Related Anal Cancer on the Rise
More than 7,200 cases of anal cancer were diagnosed in 2014—approximately 2,600 in men and 4,600 in women—representing an increase of more than 4,000 from 8 years ago. In more than 90% of patients, infection with the human papillomavirus (HPV) is the cause, tagging anal cancer as a largely...
Managing Breast Cancer in 2015
Since 1990, we have seen an approximate 35% reduction in breast cancer mortality among women in the United States. Three protagonists can share this clinical success story: prevention, early detection, and better therapies. To shed light on the current state of breast cancer research and therapy,...
Prostate Tumors With Genetic Abnormalities Respond to Olaparib
Olaparib (Lynparza) achieved encouraging response rates in men with metastatic prostate cancer, particularly those with mutations in genes involved in DNA repair (BRCA2 and ATM, most commonly).1 If validated, these results of the TOPARP-A trial will usher in the first drug targeted to somatic or...
Many Miles to Go: Targeted Treatment Based on Whole-Genome Sequencing
The ability to do genomic analysis of patients’ tumors holds great promise for revolutionizing cancer treatment, and genomics has already made some great strides. However, the Individualized Molecular Pancreatic Cancer Therapy (IMPaCT) trial is a cautionary tale about the hurdles involved in...
Pembrolizumab Safe and Effective in Patients With NSCLC, Especially in Those With Tumors Showing High Levels of PD-L1 Expression
Add lung cancer to the growing list of cancers that may derive benefit from immunotherapy. The KEYNOTE-001 trial found that pembrolizumab (Keytruda) achieved durable responses in a proportion of patients with non–small cell lung cancer (NSCLC) and high levels of expression of the protein PD-L1...
Genomic Analyses Point to the Potential of Personalized Care for Liver Cancer Patients
A new study presented at The International Liver Congress™ 2015 in Vienna, Austria, showed that by using genomic analyses to understand how and when carcinogenic mutations occur in patients with hepatocellular carcinoma, it is possible to identify specific molecular profiles. It is hoped that these ...
NCCN Presents Rodger Winn Award to Daniel G. Coit, MD
At the 20th Annual Conference of the National Comprehensive Cancer Network (NCCN) held in March 2015 in Hollywood, Florida, NCCN presented Daniel G. Coit, MD, with the Rodger Winn Award. The award, named for NCCN’s “founding father” of the Guidelines Program and the first Editor-in-Chief of the...
Simple Means of Preventing Nonmelanoma Skin Cancer Reported
Two daily doses of nicotinamide, a form of vitamin B3, significantly reduced the occurrence of nonmelanoma skin cancers by 23% in individuals considered at high risk for these lesions in an Australian study. Results of the phase III ONTRAC trial, which will be presented at the 2015 ASCO Annual...
Expert Point of View: Philip L. McCarthy, MD
Another exciting multiple myeloma treatment will be presented at the 2015 ASCO Annual Meeting,” Philip L. McCarthy, MD, Professor of Oncology and Director of the Blood and Marrow Transplant Center at Roswell Park Cancer Institute, Buffalo, New York, commented in an interview with The ASCO Post....
Novel Agent Elotuzumab Added to Lenalidomide/Dexamethasone Extends Progression-Free Survival in Multiple Myeloma
The monoclonal antibody elotuzumab, given with lenalidomide (Revlimid) and dexamethasone, extended progression-free survival by a median of 5 months, compared with lenalidomide/dexamethasone alone, in the eagerly awaited phase III ELOQUENT-2 trial, which will be presented at the 2015 ASCO Annual...
Docetaxel Combined With Hormone Therapy Extends Survival in Advanced Prostate Cancer
Results from the STAMPEDE trial showed that the addition of docetaxel to standard hormone therapy improved overall survival by a median of 10 months over hormone therapy alone in men with newly diagnosed, advanced, hormone therapy–naive prostate cancer.1 The study also showed that zoledronic acid...
In Memoriam: Dorothy ‘Dottie’ Thomas
Dorothy “Dottie” Thomas was wife and research partner to 1990 Nobel laureate E. Donnall Thomas, MD, pioneer of the bone marrow transplant and former Director of the Clinical Research Division at Fred Hutchinson Cancer Research Center. Dr. and Mrs. Thomas formed the core of a team that proved bone...
In Memoriam: Jesse L. Steinfeld, MD
In 1971, then Surgeon General Jesse L. Steinfeld, MD, took Big Tobacco to task, stating, “Let me suggest that certain purveyors of cigarettes stop making remarks about how some young mothers in childbirth might welcome smaller babies. The mother who smokes is subjecting the unborn child to the...
A Tribute to James F. Holland, MD, in Celebration of His 90th Birthday
Far and away the best prize that life has to offer is the chance to work hard at work worth doing. —Theodore Roosevelt Longevity, in and of itself, is not an accomplishment. Luck and good genes are just human lottery tickets. Most people fortunate enough to live long lives have a productive sweet ...
After a Long and Distinguished Career, Robert C. Young, MD, Shows No Sign of Slowing Down
Robert C. Young, MD, ASCO Past President, longtime leader of Fox Chase Cancer Center, and an internationally recognized expert in lymphoma and ovarian cancer, is a forward-looking doctor who is confident about something not in his future: retirement. “I’ll never quit working; I’m just not wired...
Wyndham H. Wilson, MD, PhD: Shedding Light on the Complexity of Lymphoma Through a Lifetime of Illuminating Research
Dear Dr. Wilson: I am writing to express our family’s deepest and heartfelt appreciation for the lifesaving care you and your team provided for our son, Patrick…. I don’t know how widely it is known that you save lives at the National Cancer Institute—offering hope to people like Patrick, who have...
Andrew C. von Eschenbach, MD, Went From the Front Lines of Cancer Care to a Bird’s-Eye View of the Changing Oncology Landscape
At the end of the day, I’m still a kid from South Philly,” Andrew C. von Eschenbach, MD, former Director of the National Cancer Institute (NCI) and Commissioner of the U.S. Food and Drug Administration (FDA), told The ASCO Post. Dr. von Eschenbach is the product of a closely knit yet culturally...
Nationally Recognized Leader in Myeloid Malignancies, Alan F. List, MD, Has High Hopes for the Future of Oncology
The Tampa Bay area of Florida is a haven for golfers and fishermen looking to unwind under the warm tropical skies. And the clean highways stretching through the scenic west coast of Florida are also a perfect excuse for weekend motorcycle enthusiasts, such as Alan F. List, MD, the President and...
Lymphoma Expert and Industry Leader Sandra J. Horning, MD, Pushes the Frontiers of Drug Development and Oncology Research
Due to childhood health issues, Sandra J. Horning, MD, formed an opinion about doctors at a young age: They were good people who helped other people. By her early teens, Dr. Horning began to ponder a career in medicine, which offered the possibility of blending her love of science with a career...
Pioneer in Combination Chemotherapy, Vincent T. DeVita, Jr, MD, Changed the Face of Modern Oncology
As a young boy growing up in the Bronx, Vincent T. DeVita, Jr, MD, admired the local iceman, a thick-muscled guy known as Nunzi, who used to carry a big block of ice on his shoulder with a set of tongs, and effortlessly slide it into the DeVitas’ icebox. “A friend once asked me what I wanted to be...
Bruce A. Chabner, MD, and His Innovative Pharmacology Research Led to the Development of Practice-Changing Therapies
Numerous challenges and milestones mark the course of an oncology career. Community doctors remember special patients, often speaking about a singular bond that is unique among a profession that deals with life and death daily. Researchers recount long hours of seeming futility and then the...
‘Father of Geriatric Oncology’ Lodovico Balducci, MD, Unearthed a New Understanding of Aging’s Effect on Cancer Treatment
At the 2007 ASCO Annual Meeting, Lodovico Balducci, MD, received the inaugural B.J. Kennedy Award and Lecture for Scientific Excellence in Geriatric Oncology. Called the “patriarch of geriatric oncology,” Dr. Balducci is widely known in the oncology community for his warm humor and thick Italian...
Carolyn R. ‘Bo’ Aldigé Reflects on 30 Years of Cancer Prevention
In 1985, Carolyn R. “Bo” Aldigé founded the Prevent Cancer Foundation in honor of her father, who had died the previous year of head and neck cancer. She started the Foundation in her kitchen with a typewriter, a sheath of carbon copy paper, and a telephone. “I quickly rented an office because a...
More Extensive Lymph Node Clearance During Surgery for Esophageal Cancer May Not Improve Survival
A population-based cohort study “indicates that more extensive lymph node clearance during surgery for esophageal cancer may not improve survival,” Maartje van der Schaaf, MD, PhD, of the Karolinska Institutet, Stockholm, and colleagues reported in the Journal of the National Cancer Institute....
First-Line Imatinib With Early Switch to Nilotinib May Be Preferable to First-Line Use of More Potent Agents in CML
Using imatinib to treat chronic-phase chronic myeloid leukemia (CP-CML) first line, with selective switching to nilotinib (Tasigna) “leads to excellent molecular response and survival” and “may be preferable to universal first-line use of more potent agents, considering efficacy, toxicity, and...
POLE Proofreading Mutations Predict Better Outcome in Endometrial Cancer
In a study reported in the Journal of the National Cancer Institute, Church and colleagues assessed whether proofreading mutations in POLE (which encodes the DNA polymerase epsilon catalytic subunit) were associated with prognosis in endometrial cancer. Such mutations have been reported in...
Effect of ERG Gene Status on Progression-Free Survival With Abiraterone in Castration-Resistant Prostate Cancer
Gene fusions resulting in androgen receptor–modulated ERG gene overexpression can be found in up to 70% of patients with metastatic castration-resistant prostate cancer. In a study reported in Clinical Cancer Research, Attard and colleagues assessed the effect of ERG rearrangement on outcomes in...
Incidence of Fractures Is ‘Compellingly Higher’ After Hematopoietic Stem Cell Transplantation
The incidence of fractures is “compellingly higher” after receiving hematopoietic stem cell transplantation, according to a retrospective study of patients receiving transplants for treatment of multiple myeloma, other hematologic malignancies, and some solid tumors (mostly breast and ovarian) as...
Cancer Will Always Be Part of My Life
My first experience with cancer was when I was just 9 years old, and a lump the size of an egg popped out on the right side of my neck. A biopsy of the tumor found that it was Hodgkin lymphoma, and I was given huge doses of external-beam radiotherapy applied to my neck, chest, and underarm lymph...
Another Angiogenesis Inhibitor Shows Benefit in Metastatic Colorectal Cancer, but Where Do We Go Next?
The phase III RAISE trial—reported by Tabernero and colleagues in The Lancet Oncology1 and reviewed in this issue of The ASCO Post—demonstrated that ramucirumab (Cyramza), a fully human IgG1 monoclonal antibody to the vascular endothelial growth factor receptor 2 (VEGFR2) extracellular domain, in...
Addition of Ramucirumab to Second-Line FOLFIRI Improves Overall Survival in Metastatic Colorectal Cancer
In the phase III RAISE trial reported in The Lancet Oncology, Josep Tabernero, MD, PhD, Head of Medical Oncology at Vall d’Hebron Institute of Oncology, Barcelona, and colleagues found that the addition of the antiangiogenic anti–vascular endothelial growth factor receptor 2 (VEGFR2) antibody...
Nancy Brinker Named May LUNGevity Hero
The LUNGevity Foundation has announced Nancy Brinker, Founder and Chief of Global Strategy of Susan G. Komen, as the May LUNGevity Hero in recognition of her decades-long dedication and trailblazing work in the fight against cancer. A true pioneer of the advocacy movement, Ms. Brinker gave a...
Fulfilling NCI’s Commitment to Supporting the Best Science
On April 1, 2015, Douglas R. Lowy, MD, became Acting Director of the National Cancer Institute (NCI), succeeding Harold Varmus, MD, who left NCI to join the faculty of Weill Cornell Medical College in New York. (See “The Next Step in a Storied Career,” in the May 25, 2015 issue of The ASCO Post.)...
Nivolumab Increases Response Rate vs Chemotherapy in Advanced Melanoma Progressing After Anti–CTLA-4 Treatment
In a phase III trial (CheckMate 037) reported in The Lancet Oncology, Jeffrey S. Weber, MD, PhD, of the Moffitt Cancer Center, and colleagues found that treatment with the PD-1 (programmed cell death protein 1) inhibitor nivolumab (Opdivo) resulted in a significantly greater response rate vs...
First National Data on Breast Cancer Subtypes Mark New Era in Biomarker Epidemiology
This year’s Report to the Nation on the Status of Cancer contains the first national combined data set on the incidence of four major breast cancer subtypes by race/ethnicity, poverty level, geography, and other factors. The findings show that “there are unique racial/ethnic-specific incidence...
Outcomes of the CUSTOM ‘Basket’ Trial of Molecular Profiling and Targeted Therapy in Advanced Thoracic Malignancies
In the phase II CUSTOM trial reported in the Journal of Clinical Oncology, Ariel Lopez-Chavez, MD, Anish Thomas, MD, and colleagues performed molecular profiling of tumors in patients with advanced non–small cell lung cancer (NSCLC), small cell lung cancer (SCLC), or thymic malignancies and...
What Is the Future of Intraperitoneal Treatment in Advanced Ovarian Cancer?
An analysis of Gynecologic Oncology Group (GOG) studies recently reported in the Journal of Clinical Oncology by Tewari and colleagues and reviewed in this issue of The ASCO Post showed a survival benefit of intraperitoneal chemotherapy vs intravenous chemotherapy over long-term follow-up in women...
Long-Term Survival Advantage Seen With Intraperitoneal vs Intravenous Chemotherapy in Advanced Ovarian Cancer
In an analysis of Gynecologic Oncology Group (GOG) studies reported in the Journal of Clinical Oncology, Devansu Tewari, MD, of Kaiser Permanente Irvine Medical Center, and colleagues found that intraperitoneal chemotherapy was associated with a survival advantage compared with intravenous...
Expert Point of View: Aditya Bardia, MD
These results are promising. The fact that there were two patients with a complete response caught my eye. This is very exciting in metastatic triple-negative breast cancer. These were heavily pretreated patients; 85% had more than four lines of prior therapy,” said Aditya Bardia, MD, a breast...
Anti–PD-L1 Agent Shows Activity in Early Study of Triple-Negative Breast Cancer
An investigational immunotherapy called MPDL3280A showed encouraging and durable clinical activity in heavily pretreated patients with metastatic triple-negative breast cancer, in an early study presented at the 2015 Annual Meeting of the American Association of Cancer Research (AACR).1 Responses...
Studies Evaluate Effectiveness of Active Surveillance in Prostate Cancer Patients
Active surveillance has become a viable option for many men with low-risk prostate cancer who choose not to undergo active treatment such as surgery or radiotherapy. Four studies evaluating the effectiveness, trends, and other considerations for active surveillance in managing prostate cancer were...
New Studies Call for Smarter Approach to Prostate Cancer Screening
Prostate cancer is one of the most common cancers in American men, yet controversy over the utilization and frequency of prostate-specific antigen (PSA) screening methods remains, due to the overdiagnosis and overtreatment of men with low-grade, less-aggressive forms of the disease. At the 110th...
Nipple-Sparing Mastectomy Shown to Be Oncologically Safe
Mastectomies that preserve the nipple and an envelope of breast skin are as safe as more radical operations for qualifying early-stage breast cancer patients, according to a meta-analysis and systematic literature review presented at the American Society of Breast Surgeons 16th Annual Meeting.1...
Expert Point of View: Alison M. Friedmann, MD
Commenting on the AREN0532/AREN0533 data, Alison M. Friedmann, MD, of the Department of Hematology/Oncology at Massachusetts General Hospital, Boston, said that this is an important study. “This continues to build on the highly successful risk-adapted treatment approach of the previous National...
Intensified Therapy Improves Survival in Wilms Tumor Patients With Rare Genetic Abnormality
Data from two phase III studies led by the Children’s Oncology Group show that augmenting or intensifying therapy for children with high-risk Wilms tumor improved relapse-free survival. These children are deemed to be at high risk due to a specific chromosomal abnormality that confers worse...
Whole-Brain Radiation: Risks Outweigh Benefits for Limited Brain Metastases
New data from a phase III Alliance trial weighs in on a longstanding debate in the treatment of brain metastases: Should whole-brain radiation therapy be added to stereotactic radiosurgery? The study found that although whole-brain radiation therapy improved local tumor control in patients with...
Clinically Meaningful Preliminary Results With Pembrolizumab in Recurrent Head and Neck Cancer
Pembrolizumab (Keytruda) is making inroads into head and neck cancer, with encouraging results in heavily pre-treated patients with recurrent or metastatic squamous cell carcinoma of the head and neck, according to a report on the expansion-cohort KEYNOTE-012 study presented at the 2015 ASCO...
